Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Maersk shares surge despite weaker 2025 earnings outlook on tariff fears

(Sharecast News) - Shares in Danish shipping giant Maersk surged on Thursday after the firm posted better-than-expected fourth-quarter profits, but warned annual earnings would be lower due to geopolitical uncertainties such as US tariffs. Maersk said it expected underlying core earnings of $6bn - $9bn compared with last year's $12.1bn and 2023's $9.6bn.

Fourth-quarter underlying earnings before interest, tax, depreciation and amortisation (EBITDA) came in at $3.60bn. Analysts had forecast EBITDA of $3bn. Maersk shares spiked by almost 10% in European trade.

"The list of geopolitical strains on supply chains continues to expand with uncertainty over heightened tariffs on U.S. imports as well as tighter export controls on critical goods, sanctions and a renewed interest in industrial policies," Maersk said.

"The impact of U.S. tariffs will be larger depending on their level, the coverage of countries and goods, partners' retaliation and the risk of tariffs in third countries against Chinese manufactured goods as they look for new markets."

Maersk's guidance was based on expectations that global container volume growth in 2025 will be around 4% and the company would grow in line with the market.

"It is further expected that 2025 is likely to show greater supply-demand imbalance with continued new deliveries in the container shipping industry and a potential re-opening of the Red Sea. Nevertheless, this imbalance may be largely offset by supply-side drivers and strong market demand," it added.

Reporting by Frank Prenesti for Sharecast.com

Share this article

Related Sharecast Articles

GSK gets preliminary nod for two respiratory drugs in Europe
(Sharecast News) - GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use, bringing the company closer to potential approvals across severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease.
Shore Capital hails improved US biotech funding environment for hVIVO
(Sharecast News) - Shares in AIM-listed hVIVO were continuing their recent surge on the back of encouraging signs from the US biotech market, which broker Shore Capital said has created a "much more favourable environment" for the company.
Weir to buy remaining 50% stake in Chile JV ESEL for £56m
(Sharecast News) - Weir said on Friday that it has agreed to buy the remaining 50% share of its Chile-based joint venture ESEL for a sterling equivalent purchase price of £56m.
Jefferies downgrades Whitbread, upgrades IHG
(Sharecast News) - Jefferies downgraded Whitbread to 'hold' from 'buy' on Friday as it applied the reverse upgrade to InterContinental Hotels.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.